Heart Medication Entresto Does Not Increase Angioedema Risk Compared with Standard Therapy, Study Finds
Entresto (sacubitril/valsartan) — an approved medication for heart failure — does not significantly increase the risk of angioedema compared with standard therapy Vasotec (enalapril), data from a Phase 3 trial show. The medication was also better at preventing deaths and heart failure-related hospitalizations than Vasotec, suggesting it could…